Health-Holland

With an unrivalled concentration of biopharmaceutical companies, world-class universities and a long history of strategic partnerships linking science, industry and government, the Netherlands is a perfect location for biopharmaceutical innovation in Europe. Many ground-breaking companies have already established themselves in the Netherlands. The EMA has also made the decision to relocate to Amsterdam. This confirms once more that the Netherlands is the perfect home for biopharmaceutical companies from around the globe. Attractive location for your company The Netherlands is a thriving and prosperous country, providing an attractive place to live and locate your business. With a geographical radius of only 120 miles, the country boasts a competitive international business climate which is reflected by its status as the sixth-largest EU economy, a major global exporter and importer of goods and a Forbes ranking as the third best country for doing business. The strategic location of the Netherlands, bordering the three largest economies in Europe (Germany, the United Kingdom and France), makes it the perfect gateway into Europe. Its superior infrastructure guarantees quick and easy access to European markets while ensuring that markets around the world are also within easy reach. Also, the country is a data & ICT hub with an excellent information technology infrastructure. Moreover, its ranking as the sixth-happiest place on earth in the World Happiness Report further demonstrates that the Netherlands is an attractive place to live. Appealing industry climate The Netherlands offers an appealing business climate with plenty of room for innovation. It has a competitive and stable tax regime, attractive incentives that support R&D, and outstanding research and educational institutions. The country is also highly regarded for its well-educated, multilingual and dynamic workforce. Concentrated biopharmaceutical ecosystem The Netherlands is home to one of the most concentrated Life Science & Health clusters in the world, featuring more than 2,900 innovative R&D Life Sciences companies, including 420 biopharmaceutical companies. These 420 companies employ over 65,000 people, both in direct and indirect employment. Scientific research in the Netherlands is highly regarded internationally. This is demonstrated by the high quality of Dutch research universities and university medical centres, its high citation impact score and the position of its universities in international rankings. The country has a rich tradition of public-private cooperation, which has been further stimulated by multiple government-initiated programs. The government actively stimulates private cash investments in public-private R&D partnerships by supplementing these investments. Most innovative biopharmaceutical environment Public and private partners in the Dutch biopharmaceutical sector have joined forces with the ambition of establishing the world’s most attractive and innovative biopharmaceutical environment. We are dedicated to further improving our excellent R&D climate for the benefit of patients. Together we can make this ambition become a reality, so come and join us to strengthen the sector further! Read all about the advantages of setting up your business in the Netherlands in this bid book. EXECUTIVE SUMMARY Discover Europe’s most attractive and innovative biopharmaceutical environment. 8